Iqvia Holdings Inc Stock Nyse
Equities
US74876Y1010
Biotechnology & Medical Research
Sales 2024 * | 15.48B 21.15B | Sales 2025 * | 16.56B 22.63B | Capitalization | 41.83B 57.16B |
---|---|---|---|---|---|
Net income 2024 * | 1.34B 1.83B | Net income 2025 * | 1.58B 2.15B | EV / Sales 2024 * | 3.47 x |
Net Debt 2024 * | 11.93B 16.31B | Net Debt 2025 * | 11.7B 15.99B | EV / Sales 2025 * | 3.23 x |
P/E ratio 2024 * |
31.3
x | P/E ratio 2025 * |
26.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70% |
Latest transcript on Iqvia Holdings Inc
Managers | Title | Age | Since |
---|---|---|---|
Ari Bousbib
CEO | Chief Executive Officer | 63 | 16-10-02 |
Ronald Bruehlman
DFI | Director of Finance/CFO | 63 | 20-07-31 |
James Berkshire
COO | Chief Operating Officer | 51 | 17-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Danhakl
BRD | Director/Board Member | 67 | 16-10-02 |
Colleen Goggins
BRD | Director/Board Member | 68 | 17-07-26 |
Ari Bousbib
CEO | Chief Executive Officer | 63 | 16-10-02 |
1st Jan change | Capi. | |
---|---|---|
+67.53% | 63.85B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B | |
-8.12% | 11.19B |